Microcap Ledger Agenus Inc $AGEN
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Lexington, MA
- Fiscal year end
- December 31
- Shares outstanding
- 45,020,407 [10-Q 2026-08-07]
What the company doesAI summary of filing
Agenus Inc. develops immunotherapy product candidates, primarily antibodies and adoptive cell therapies, targeting cancer and autoimmune diseases. The company is clinical-stage and pre-revenue, with no approved products currently on the market, though it previously submitted a biologics license application for balstilimab that was voluntarily withdrawn. Agenus generates revenue through collaboration and licensing agreements with pharmaceutical partners, receiving milestone payments and royalties, such as a 5% royalty agreement with Zydus LifeSciences for balstilimab and botensilimab in India and Sri Lanka. The company relies on third-party contract manufacturing organizations for production, external collaborators for clinical development, and plans to establish internal or partner-based sales and marketing capabilities upon potential product approval. [10-K 2026-03-16]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $68.25M | $38.64M | −$67.15M | $18.74M | [10-Q 2026-08-07] |
| FY ended Dec 2025 | $114.20M | −$3.08M | −$77.19M | $3.00M | [10-K 2026-03-16] |
| FY ended Dec 2024 | $103.46M | −$232.27M | −$158.31M | $40.44M | [10-K 2026-03-16] |
- Quarterly cash burn
- −$33.57M
- Cash runway Estimate
- ~1.7 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-08 | 23,458,929 | [10-Q 2024-11-12] |
| 2025-03-13 | 25,308,841 | [10-K 2025-03-17] |
| 2025-05-06 | 27,416,850 | [10-Q 2025-05-12] |
| 2025-08-07 | 31,864,108 | [10-Q 2025-08-11] |
| 2025-11-07 | 34,008,349 | [10-Q 2025-11-10] |
| 2026-03-12 | 38,398,354 | [10-K 2026-03-16] |
| 2026-05-07 | 41,642,431 | [10-Q 2026-05-11] |
| 2026-08-04 | 45,020,407 | [10-Q 2026-08-07] |
- Shelf registration
- S-3 filed 2026-09-11; no effectiveness notice found in EDGAR [S-3 2026-09-11]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-10-01 | Harrison Thomas L | grant | 4,443 | $6.89 | [4 2026-10-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-11 | S-3 | Registration statement |
| 2026-08-18 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-08-17 | 424B3 | Prospectus or prospectus supplement |
| 2026-08-13 | 8-K | Director or officer change |
| 2026-08-11 | 8-K | Director or officer change |
| 2026-08-07 | 10-Q | Quarterly report |
| 2026-08-07 | S-3 | Registration statement |
| 2026-08-06 | 8-K | Results of operations |
| 2026-07-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-20 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-20 | S-3 | Registration statement |
| 2026-07-17 | 13G | Beneficial ownership report (5%+ holder) |
Alerts for $AGEN
Email me when Agenus Inc files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.